Abstract

The purpose of this work was to present a consolidated set of guidelines for the analysis of uncontrolled concomitant medications (ConMed) as a covariate and potential perpetrator in population pharmacokinetic (PopPK) analyses. This white paper is the result of an industry-academia-regulatory collaboration. It is the recommendation of the working group that greater focus be given to the analysis of uncontrolled ConMeds as part of a PopPK analysis of Phase 2/3 data to ensure that the resulting outcome in the PopPK analysis can be viewed as reliable. Other recommendations include: (1) collection of start and stop date and clock time, as well as dose and frequency, in Case Report Forms regarding ConMed administration schedule; (2) prespecification of goals and the methods of analysis, (3) consideration of alternate models, other than the binary covariate model, that might more fully characterize the interaction between perpetrator and victim drug, (4) analysts should consider whether the sample size, not the percent of subjects taking a ConMed, is sufficient to detect a ConMed effect if one is present and to consider the correlation with other covariates when the analysis is conducted, (5) grouping of ConMeds should be based on mechanism (e.g., PGP-inhibitor) and not drug class (e.g., beta-blocker), and (6) when reporting the results in a publication, all details related to the ConMed analysis should be presented allowing the reader to understand the methods and be able to appropriately interpret the results.

Notes

Acknowledgments

The ISOP Working Group would like to thank the ISOP Standards and Best Practices Committee for their thoughtful comments: Nidal al-Huniti, Brian Corrigan, Thomas Dumortier, Gerard Flesch, Daniele Ouellet, and Liping Zhang.

International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Statistical Principles for Clinical Trials (E9), 1998Google Scholar

13.

United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (1999) Guidance for industry: population pharmacokineticsGoogle Scholar

Wang DD, Zhu M, Kassir N, William H, Earp JC, Chow A et al. (2013) The utility of a population approach in DDI assessments: an evaluation of using simulation approaches. In: Presented at the annual meeting of the american conference on pharmacometrics, Fort LauderdaleGoogle Scholar